Notícias

BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

Bristol Myers Squibb (NYSE:BMY) is rolling out an AI driven overhaul of its procurement operations, using tools designed to shorten sourcing timelines and reshape internal buying processes. The company is also expanding its oncology footprint through a new non exclusive clinical collaboration with Arcus Biosciences that focuses on late stage cancer drug trials. These developments come alongside earlier attention on product approvals, clinical milestones, and access programs, which have...

Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.

"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak.

Takeda said Thursday its AI-designed psoriasis pill, zasocitinib, easily beat Bristol's Sotyktu in a head-to-head study.

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.

Bristol Myers Squibb Foundation, linked to NYSE:BMY, is rolling out a new lung cancer detection and care model in underserved Brazilian communities. The program uses mobile CT units, telemedicine, and local community engagement to support earlier diagnosis and access to curative treatment. This initiative focuses on healthcare equity and may offer a template that could be applied to other regions over time. For investors following NYSE:BMY, this move extends the story beyond drug pipelines...

Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built dividend portfolio pays you on a schedule independent of whether you showed up to work or whether your employer hit its quarter. Real ... Earn $5,000+ Yearly With These 4 Dividend Stocks

BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy in patients with previously untreated advanced […]

The pharmaceutical giant cut procurement timelines from months to weeks while challenging conventional wisdom on AI data readiness.

SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The drugmaker's recent outperformance is a sideshow to its more valuable, long-term trait for investors.

Bristol Myers Squibb (NYSE:BMY) is the headline pharma name dividend hunters keep circling, drawn in by a 4.37% yield and a forward P/E of 9 that screams cheap. But the underlying numbers tell a different story. That low multiple is cheap for a reason. Bristol Myers is running headfirst into a generic cliff that the ... Forget Wall Street’s Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now

A 63-year-old retiree with $400,000 parked in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) likely picked it for the 100-stock screen and the reliable income stream. The top 10 positions now make up 41% of the fund, which means roughly $164,000 of that nest egg sits in ten names. For a fund managing $94 billion, ... SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.27, marking a +1.18% move from the previous day.

What does this smart money investor see that the market is missing?

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.

Earlier this week, the European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with AVD chemotherapy as the first immunotherapy-based frontline regimen for adults and adolescents with previously untreated Stage III or IV classical Hodgkin lymphoma in the EU. This decision expands Opdivo’s reach into earlier-stage treatment of a cancer that is especially common in adolescents and young adults, potentially broadening Bristol Myers Squibb’s hematology-oncology...

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

Bristol Myers Squibb (NYSE:BMY) received European Commission approval for Opdivo plus AVD as the first immunotherapy-based first-line regimen for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents. At ASCO 2026, the company reported late-breaking Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma, with a 52% reduction in disease progression or death. Izalontamab brengitecan Phase 3 data at the same meeting indicated meaningful survival...

Durability, not yield, is the deciding factor.

If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.